難治性好酸球性筋膜炎に対するリツキシマブおよび静脈内免疫グロブリン（IVIG）療法：症例報告

Maryam Sahebari¹, Motahhareh Karimoddini², Naser Tayyebi Meibodi³

¹Rheumatic Diseases Research Center, Mashhad University of Medical Sciences Mashhad Iran.

|January 7, 2026

Abstract:

Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40-year-old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long-term safety for EF.

キーワード:

好酸球性筋膜炎静脈内免疫グロブリン難治性好酸球性筋膜炎リツキシマブ

関連する概念動画

01:14

Myocarditis III: Medical Management

168

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

168